SubscribeorLogin

Akoury notes-2

by , , , , , , , , | Nov 1, 2014

Post Categories: Mental Health | Neurodegenerative Diseases

  1. Peniston EG, Kulkosky PJ. Alcoholic personality and alpha-theta brainwave training. Med Psychother. 1990;2:37–55.

  2. Blum K. Alcohol and central nervous system peptides. Subst Alcohol Actions Misuse. 1983;4:73–87.

  3. Gardner EL. Addiction and brain reward and antireward pathways. Adv Psychosom Med. 2011;30:22–60.

  4. Padgett CL, Lalive AL, Tan KR, et al. Methamphetamine-evoked depression of GABA(B) receptor signaling in GABA neurons of the VTA. Neuron. 2012;73:978–989.

  5. Basu S, Dasgupta PS. Dopamine, a neurotransmitter, influences the immune system. J Neuroimmunol. 2000;102(2):113–124. doi:10.1016/S0165-5728(99)00176-9. PMID 10636479.

  6. Blum K, Briggs AH, Trachtenberg MC. Ethanol ingestive behavior as a function of central neurotransmission. Experientia. 1989;45:444–452.

  7. Ibid.

  8. Blum K, Calhoun W, Merritt J, Wallace JE. L-DOPA: effect on ethanol narcosis and brain biogenic amines in mice. Nature. 1973;242:407–409.

  9. Blum K, Trachtenberg MC (1988) Neurogenetic deficits caused by alcoholism: restoration by SAAVE, a neuronutrient intervention adjunct. J Psychoactive Drugs. 20:297–313.

  10. Brown RJ, Blum K, Trachtenberg MC. Neurodynamics of relapse prevention: a neuronutrient approach to outpatient DUI offenders. J Psychoactive Drugs. 1990;22:173–187.

  11. Chen D, Liu Y, He W, Wang H, Wang Z. Neurotransmitter-precursor-supplement intervention for detoxified heroin addicts. J Huazhong Univ Sci Technolog Med Sci. 2012;32: 422–427.

  12. Blum K, Trachtenberg MC. Neurogenetic deficits caused by alcoholism: restoration by SAAVE, a neuronutrient intervention adjunct. J Psychoactive Drugs. 1988;20:297–313.

  13. Chen et al. 2012. Op cit.

  14. Trachtenberg MC, Blum K Improvement of cocaine-induced neuromodulator deficits by the neuronutrient tropamine. J Psychoactive Drugs 1988;20:315–331.

  15. Hyman SE, Malenka RC, Nestler EJ. Neural mechanisms of addiction: the role of reward-related learning and memory. Annu Rev Neurosci. 2006;29: 565–598. doi:10.1146/annurev.neuro.29.051605.113009. PMID 16776597.

  16. Hu XJ, Ticku MK. Chronic benzodiazepine agonist treatment produces functional uncoupling of the gamma-aminobutyric acid-benzodiazepine receptor ionophore complex in cortical neurons. Mol Pharmacol. 1994;45:618–625.

  17. Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1999;20(3):201–225. doi:10.1016/S0893-133X(98)00060-8. PMID 10063482.

  18. Hu XJ, Ticku MK. Chronic benzodiazepine agonist treatment produces functional uncoupling of the gamma-aminobutyric acid-benzodiazepine receptor ionophore complex in cortical neurons. Mol Pharmacol. 1994;45:618–625.

  19. Blum K, Chen ALC, Chen TJH, et al. Putative targeting of dopamine D2 receptor function in reward deficiency syndrome (RDS) by Synaptamine Complex™ Variant (KB220): clinical trial showing anti-anxiety effects. Gene Ther Mol Biol. 2009;13:214–230.

  20. Trachtenberg and Blum. 1998. Op cit.

  21. Dahlström A, Fuxe K. Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol Scand Suppl. 1964;232:1–55. PMID 14229500.

  22. Buttarelli FR, Fanciulli A, Pellicano C, Pontieri FE. The dopaminergic system in peripheral blood lymphocytes: from physiology to pharmacology and potential applications to neuropsychiatric disorders. Curr Neuropharmacol June 2011;9(2):278–288. doi:10.2174/157015911795596612. PMC 3131719. PMID 22131937.

  23. Grace AA, Bunney BS. The control of firing pattern in nigral dopamine neurons: single spike firing. J Neurosci. 1984;4(11):2866–2876. PMID 6150070.

  24. Barron AB, Søvik E, Cornish JL. The roles of dopamine and related compounds in reward-seeking behavior across animal phyla. Front Behav Neurosci. 2010;4:163. doi:10.3389/fnbeh.2010.00163. PMC 2967375. PMID 21048897.

  25. Jenner P, Marsden CD. Chronic pharmacological manipulation of dopamine receptors in brain. Neuropharmacology. 1987;26:931–940.

  26. Schultz W. Multiple dopamine functions at different time courses. Annu Rev Neurosci. 2007;30:259–288. doi:10.1146/annurev.neuro.28.061604.135722. PMID 17600522.

  27. Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the eitiology of schizophrenia. Neuroscience. 1991;41(1):1–24. doi:10.1016/0306-4522(91)90196-U. PMID 1676137.

  28. Merims D, Giladi N. Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson’s disease. Parkinsonism Relat Disord. 2008;14(4):273–280. doi:10.1016/j.parkreldis.2007.09.007. PMID 17988927.

  29. Grace and Bunney. 1984. Op cit.

  30. Calabresi P, Picconi B, Tozzi A, Di Filippo M. Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci. May 2007;30 (5):211–219. doi:10.1016/j.tins.2007.03.001. PMID 17367873.

  31. Hyman et al. 2006. Op cit.

  32. Birkmayer W, Linauer W, Storung D. Tyrosin and tryptophan- metabolisms in depression patients. Arch Psychiar Nervenkr. 1970;213(4):377–387. doi:10.1007/BF00341554.

  33. Blum et al. 2009. Op cit.

  34. Jenner P, Marsden CD. Chronic pharmacological manipulation of dopamine receptors in brain. Neuropharmacology. 1987;26:931–940.

  35. Centonze D, Picconi B, Baunez C, Borrelli E, Pisani A, et al. Cocaine and amphetamine depress striatal GABAergic synaptic transmission through D2 dopamine receptors. Neuropsychopharmacology. 2002;26:164–175.

  36. Wise RA. Addictive drugs and brain stimulation reward. Annu Rev Neurosci. 1996;19:319–340. doi:10.1146/annurev.ne.19.030196.001535. PMID 8833446.

  37. Dahlström and Fuxe. 1964. Op cit.

  38. Robbins TW, Arnsten AF. The neuropsychopharmacology of fronto-executive function: monoaminergic modulation. Annu Rev Neurosci. 2009;32:267–287. doi:10.1146/annurev.neuro.051508.135535. PMC 2863127. PMID 19555290.

  39. Eisenhofer G, Kopin IJ, Goldstein DS. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev. September 2004;56(3):331–49. doi:10.1124/pr.56.3.1. PMID 15317907.

  40. Cottrell GA. Occurrence of dopamine and noradrenaline in the nervous tissue of some invertebrate species. Br J Pharmacol Chemother. January 1967;29 (1):63–69. doi:10.1111/j.1476-5381.1967.tb01939.x. PMC 1557178. PMID 19108240.

  41. Galani VJ, Rana DG. Depression and antidepressants with dopamine hypothesis-A review. Int J Pharm Front Res. 2011;1(2):45–60.

  42. Miller, GM. The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity. J Neurochem. January 2011;116(2):164–176. doi:10.1111/j.1471-4159.2010.07109.x. PMC 3005101. PMID 21073468.

  43. Galani and Rana. 2011. Op cit.

  44. Wood PB. Role of central dopamine in pain and analgesia. Expert Rev Neurother. 2008;8(5):781–797. doi:10.1586/14737175.8.5.781. PMID 18457535.

  45. Peniston and Kulkosky. 1990. Op cit.

  46. Dahlström and Fuxe. 1964. Op cit.

  47. Robbins and Arnsten. 2009. Op cit.

  48. Birkmayer et al. 1970. Op cit.

  49. Morón JA, Brockington A, Wise RA, Rocha BA, Hope BT. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci. 2002;22(2):389–395. PMID 11784783.

  50. Galani and Rana. 2011. Op cit.

  51. Kosterlitz HW, Hughes J. Peptides with morphine-like action in the brain. Br J Psychiatry. 1977;130:298–304.

  52. Padgett et al. 2012. Op cit.

  53. Barron et al. 2010. Op cit.

  54. Miyazaki I, Asanuma M. Dopaminergic neuron-specific oxidative stress caused by dopamine itself. Acta Med Okayama. June 2008;62(3):141–150. PMID 18596830.

  55. Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev. 2001;22(6):724–763. eishendoi:10.1210/er.22.6.724. PMID 11739329.

  56. Benkert O, Renz A, Marano C, Matussek N. Altered tyrosine daytime plasma levels in endogenous depressive patients. Arch Gen Psychiatry. October 1971;25(4):359–363. doi:10.1001/archpsyc.1971.01750160071013. PMID 5116991.

  57. Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis. 2004;16:1–13.

  58. Hawkins RA, O’Kane RL, Simpson IA, Viña JR. Structure of the blood-brain barrier and its role in the transport of amino acids. J Nutr. 2006;136:218S–26S.

  59. Benkert et al. 1971. Op cit.

  60. Birkmayer et al. 1970. Op cit.

  61. Morón et al. 2002. Op cit.

  62. Blum et al. 2009. Op cit.

  63. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. Physiol Rev. 1998;78 (1):189–225. PMID 9457173.

  64. Durcan MJ, Rigdon GC, Norman MH, Morgan PF. Is clozapine selective for the dopamine D4 receptor? Life Sci. 1995;57(18):PL275–PL283. doi:10.1016/0024-3205(95)02151-8. PMID 7475902.

  65. Ainsworth K, Smith SE, Zetterström TS, Pei Q, Franklin M, Sharp T. Effect of antidepressant drugs on dopamine D1 and D2 receptor expression and dopamine release in the nucleus accumbens of the rat. Psychopharmacology (Berl). December 1998;140(4):470–477. doi:10.1007/s002130050791. PMID 9888623.

  66. Bowirrat A, Oscar-Berman M. Relationship between dopaminergic neurotransmission, alcoholism, and reward deficiency syndrome. Am J Med Genet B Neuropsychiatr Genet. 2005;132B:29–37.

  67. Morón et al. 2002. Op cit.

  68. Bowirrat and Oscar-Berman. Op cit.

  69. Wang GJ, Smith L, Volkow ND, Telang F, Logan J, et al. Decreased dopamine activity predicts relapse in methamphetamine abusers. Mol Psychiatry. 2012;17:918–925.

  70. Miller M, Chen AL, Stokes SD, et al. Early intervention of intravenous KB220IV – neuroadaptagen amino-acid therapy (NAAT) improves behavioral outcomes in a residential addiction treatment program: a pilot study. J Psychoactive Drugs. 2012;44(5):398–409.

  71. Ibid.

  72. Miller M, Chen ALC, Stokes S, et al. Early intervention of intravenous KB220IV- Neuroadaptagen Amino-Acid Therapy (NAAT)™ improves behavioral outcomes in a residential addiction treatment program: a pilot study. J Psychoactive Drugs. 2012.

  73. Blum K, Trachtenberg MC, Ramsay JC. Improvement of inpatient treatment of the alcoholic as a function of neurotransmitter restoration: a pilot study. Int J Addict. 1988;23:991–998.

  74. Braverman ER, Braverman D, Acrui V, Kerner M, Downs BW, et al. Sustainable weight loss and muscle gain utilizing the Rainbow Diet™: targeting noradrenergic and dopaminergic mechanistic sites, hormonal deficiency repletion therapy and exercise: a case report. Am J Bariatr Med. 2010;25:18–28.

  75. Trachtenberg MC, Blum K. Improvement of cocaine-induced neuromodulator deficits by the neuronutrient Tropamine. J Psychoactive Drugs. 1988;20:315–331.

  76. Diana M. The dopamine hypothesis of drug addiction and its potential therapeutic value. Front Psychiatry. 2011;2:64.

  77. Malenka RC, Nestler EJ, Hyman SE. Chapter 15: Reinforcement and addictive disorders. In: Sydor A, Brown RY. Molecular Neuropharmacology: A Foundation for Clinical Neuroscience. 2nd ed. New York: McGraw-Hill Medical; 2009:384–385. ISBN 9780071481274.

  78. Giordano J, Blum K. Probing the mysteries of recovery through nutrigenomics and holistic medicine: Science meets recovery. Counselor Magazine. 2010;17:52.

  79. Blum K, Giordano J, Morse S, Anderson A, Carbajal J, et al. Hypothesizing synergy between acupuncture/auriculotherapy and natural activation of mesolimbic dopaminergic pathways: putative natural treatment modalities for the reduction of drug hunger and relapse. Inter Integr Omics Appl Biotechnol Lett. 2011.

  80. Basu and Dasgupta. 2000. Op cit.

Authors

Already Subscribed?

Log In

Search

Formatting updates are ongoing for older articles.

Author

Alice W. Lee-Bloem, MD

Featured Articles

Where are your Clinical Trials?

It has proven to be difficult, if not impossible, to proceed to full-scale randomized controlled trials (RCTs) for most of the natural methods that cannot be patented or otherwise monopolized. 

A Renewed Focus on Self-Help for Healing

As the producer of The Moss Report, the year leading up to the Covid-19 pandemic was filled with anticipation and excitement. We had invested years of hard work and significant resources into two major projects: our feature film, Immunotherapy: The Battle Within, and...

Issue Archives

Event Calendar

Events

Today

  • 2026 Association of Natural Health Conference

    Douglasville Conference Center Douglasville, GA, United States

    "From Practitioner to Leader: Clinical Excellence, Business Mastery & Sustainable Practice" Discover how clinical excellence, business mastery, and sustainable systems can help practitioners grow into confident leaders and build practices designed for long-term impact. Why Attend? Three days of learning, connection, and growth designed for every stage of your practice journey. Learn from Leading Voices Gain insights from top experts in natural health, holistic wellness, and functional medicine. Hands-On Learning Participate in in-depth workshops, real-world case studies, and interactive sessions you can apply immediately. Meaningful Networking Connect with like-minded professionals, students, and exhibitors who share your passion for natural health. Practical Tools & Approaches Explore new strategies and tools to elevate both your practice and your own health journey. Who Should Attend? This conference is built for a wide community of natural health professionals, educators, and advocates - wherever you are in your journey. Licensed & Clinical Practitioners Doctors, chiropractors, acupuncturists, naturopaths, and functional or integrative medicine practitioners looking to sharpen clinical skills and grow into stronger practice leaders. Allied Health Professionals Bio-feedback technicians and other allied practitioners seeking hands-on training and the latest tools in natural and holistic care. Educators & Students Natural health educators and students entering the […]

  • Food as Medicine Global 2026

    Virtual Event

    Join health professionals, farmers, food producers, researchers, educators, nonprofit leaders, chefs, policymakers, community organizers, food advocates, public health practitioners, nutritionists, and other changemakers as we convene to share knowledge, build partnerships, and explore new possibilities for improving health, strengthening communities, and creating more equitable and sustainable food systems. This year’s program features inspiring speakers and practical examples of collaboration at the intersection of food, health, social justice, and planetary well-being. Together, we’ll explore innovative approaches to Food as Medicine, community-led initiatives, nutrition, public health, regenerative agriculture, and equitable access to healthy food. Whether you work in health care, agriculture, food production, education, research, policy, or community development, you will discover new ideas, meaningful connections, and practical strategies to advance healthier, more resilient communities. Virtual  |  Join from anywhere in the world Check out the Program: https://tinyurl.com/Food-as-Medicine-for-All

  • The Midlife Women’s Health Summit: Evidence-Based Menopause Care in the Era of Longevity Medicine

    The Ritz-Carlton, Pentagon City 1250 S Hayes St, Arlington, VA, United States
    Hybrid Event

    Menopause Care in the Longevity Era Longevity medicine is everywhere right now. Supplements, protocols, influencer clinics, patients walking in with questions about interventions their doctors have never heard of. What's missing from most of it is the evidence. The Midlife Women's Health Summit is three days on what the research actually says about menopause care when you add a longevity lens. What works, what doesn't, what's being oversold, and what to tell the patient sitting in front of you. Co-chaired by Lisa Larkin, MD, FACP, MSCP, IF, Jen Gunter, MD, FRCS(C), FACOG, DABPM, ABPMR, and Lauren Streicher, MD, FACOG, MSCP; three of the clearest voices in women's health on separating data from marketing.

    $995 – $1299

Full Event Calendar

Submit Your Event

Related Posts

Are We Capable of Making Any Meaningful Changes?

By Gary Null, PhD, and Richard Gale – Do we have something to look forward to each morning, or do we carry an undiagnosed, existential dread that we’ve only now stopped long enough to notice? Have we been on the wrong path—living someone else’s life, according to someone else’s expectations, in obedience to an obligation we never chose?

Read More

, Oct 15, 2026

Feasibility and Within-Session Effects of an Integrative Therapeutic Laughter Yoga (ITLY) Protocol in Women with Self-Reported Chronic Health Conditions: A Single-Group Pre–Post Pilot Study

By Faezeh Sharif, MSc – Multi-component mind–body interventions — combining laughter yoga, diaphragmatic and slow breathing, Emotional Freedom Techniques (EFT), self-compassion practice, guided imagery, self-massage, and deep relaxation (Shavasana) — are increasingly offered in complementary and integrative health settings.

Read More

Oct 15, 2026

0 Comments

Submit a Comment